Table 1

Patient characteristics

Total group*With DRT*Without DRT*With DRT vs without DRT
Test statistic/df/p value
Number of patients1274681
Gender (f/m)43/8417/2926/55Χ2, 20.309/1/0.578
Age at DAT SPECT64.91 (10.98)64.52 (10.57)65.12 (11.27)t=0.294/125/0.769
Disease duration, years median (IQR)2.55 (2.90)3.91 (5.68)2.30 (2.17)U=2 5720.00/125/<0.001
UPDRS-III23.02 (10.68)23.05 (10.16)23 (11.02)t=−0.023/117/0.982
BAItotal scores11.50 (8.32)14.02 (9.00)10.07 (7.59)t=−2.634/125/0.010
BAIaffective scores3.85 (3.75)4.56 (4.20)3.44 (3.42)t=−1.638/125/0.104
BAI>12 (N (%) of patients)47 (37.00)21 (45.70)26 (32.10)Χ2, 22.312/1/0.128
BDI scores, median (IQR)8.00 (9.00)9.50 (9.45)7 (6.50)U=24 100.00/125/0.006
LEDD161.77 (274.78)446.64 (285.23)0
  • *Values are in mean (SD), unless otherwise specified.

  • BAI, Beck anxiety Inventory; BAI>12, clinically relevant anxiety; BDI, Beck Depression Inventory; DAT, dopamine transporter; DRT, dopamine replacement therapy; LEDD, Levodopa equivalent daily dose; SPECT, single-photon emission CT; U, Mann-Whitney U test statistic; UPDRS-III, Unified Parkinson’s Disease Rating Scale – motor symptoms.